Bayer's CEO Issues a Fertilizer Warning as the Company Unveils a Kidney Drug Breakthrough

Bayer stock near 200-day MA as CEO warns of Hormuz threat, Germany woes. Q1 revenue up but cash flow negative; Finerenon CKD trial positive.

The stock closed at €35.95 on Friday, a gain of 1.58% from the previous session, but the advance does little to mask the strain. The 200-day moving average of €35.80 is barely held, the relative strength index sits at 42.6 — a signal of mild weakness — and the 52-week high of €49.93 from February is roughly 28% away. On a 30-day view, the shares have lost nearly 7%. Two vastly different narratives are now competing to dictate where Bayer goes next.

Bill Anderson, the CEO, has drawn a direct line from a narrow shipping lane to the company’s agricultural bottom line. Around a third of the world’s trade in nitrogen-based fertilizer passes through the Strait of Hormuz, he told t-online. If that waterway remains blocked, harvests in the Northern Hemisphere could shrink significantly as early as autumn. The mechanism is indirect — Bayer does not make fertilizer — but the channel is clear: when farmers’ yields drop, they buy less seed. Anderson also flagged a potential knock-on in animal feed if corn becomes scarce, pushing up meat and egg prices. The causality, he argued, cuts straight through to the core of the agribusiness division.

Compounding the geopolitical headache, Anderson launched a sharp critique of Germany’s business climate. He called the country a "massive location disadvantage," citing high ancillary wage costs, excessive bureaucracy and energy prices that are more than triple those on the Texas Gulf Coast and more than double those in China. "I’ve been here for three years and it simply isn’t getting any better," he said. Still, he offered Chancellor Friedrich Merz a diplomatic nod of competence, stopping short of blanket complaining. Instead, he called for a "mission for Germany," arguing that the country's inventive spirit is merely sleeping, not dead.

Operationally, the first quarter of 2026 delivered a passable performance. Revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.4 billion, and adjusted EBITDA climbed 9%. Yet free cash flow sank to minus €2.32 billion, dragged down by hefty outflows to settle legal cases, particularly over PCBs and glyphosate. That cash drain underscores the financial leash around the company’s neck even as research delivers encouraging news.

On the pharmaceutical side, Bayer unloaded two significant datasets on Finerenon, the drug marketed as Kerendia and one of the few growth engines in the pharma portfolio. The centerpiece is the Phase III FIND-CKD trial, disclosed on June 5. In adults with non-diabetic chronic kidney disease, Finerenon slowed kidney function decline significantly compared with placebo — the between-group difference in eGFR slope was 0.7 mL/min/1.73 m² per year. A combined cardiorenal secondary endpoint fell by 23%. The results were simultaneously presented at the 63rd ERA Congress and published in the New England Journal of Medicine, ensuring maximum scientific exposure. Bayer now plans to submit the data to health authorities to expand Finerenon’s label, though no timeline or decision forecast was given.

Alongside FIND-CKD, Bayer released the INFINITY analysis, a prespecified pooled dataset from three completed Phase III studies — FIDELIO-DKD, FIGARO-DKD and FIND-CKD — totaling roughly 14,500 patients. Finerenon cut the primary composite renal endpoint by 24% versus placebo, while hospitalization for heart failure or cardiovascular death fell by 20%. That evaluation appeared concurrently in The Lancet.

The breadth of the evidence base is striking. Three completed Phase III trials pooled together give regulators an unusually solid foundation for assessment. Finerenon is already prescribed for diabetic kidney disease, and an expanded indication could materially widen its market. In the first quarter, Bayer’s pharma division booked €4.249 billion in revenue, virtually flat on a year ago, propped up by gains from Kerendia and the prostate cancer drug Nubeqa but eroded by patent expiries on older products.

The stock’s recovery remains fragile. The analyst consensus target of €48.82 — backed by buy ratings from nine of 11 analysts — implies substantial upside from the current level. Whether the market will treat the Finerenon data as a credible catalyst, or remain fixated on Anderson’s dual-front warning of a fertilizer shock and domestic decay, will become clearer as the week unfolds.